Значение антагонистов антилейкотриеновых препаратов в лечении разных фенотипов бронхиальной астмы
Значение антагонистов антилейкотриеновых препаратов в лечении разных фенотипов бронхиальной астмы
Княжеская Н.П. Значение антагонистов антилейкотриеновых препаратов в лечении разных фенотипов бронхиальной астмы. Consilium Medicum. Болезни органов дыхания (Прил.). 2015; с. 21–25.
________________________________________________
Kniazheskaia N.P. Meaning of antileukotriene antagonist drugs in the treatment of different phenotypes of asthma. Consilium Medicum. Respiratory organs diseases. (Suppl.). 2015; p. 21–25.
Значение антагонистов антилейкотриеновых препаратов в лечении разных фенотипов бронхиальной астмы
Княжеская Н.П. Значение антагонистов антилейкотриеновых препаратов в лечении разных фенотипов бронхиальной астмы. Consilium Medicum. Болезни органов дыхания (Прил.). 2015; с. 21–25.
________________________________________________
Kniazheskaia N.P. Meaning of antileukotriene antagonist drugs in the treatment of different phenotypes of asthma. Consilium Medicum. Respiratory organs diseases. (Suppl.). 2015; p. 21–25.
Изучение цистеиновых лейкотриенов, продуктов липоксигеназного метаболизма арахидоновой кислоты как медиаторов воспаления при бронхиальной астме (БА) позволило разработать и внедрить относительно новый класс препаратов – антагонистов лейкотриеновых рецепторов. Их противовоспалительное действие позволяет достичь контролируемого течения БА как в виде монотерапии при легком течении БА, так и в комбинации с другими противоастматическими препаратами при более тяжелых вариантах течения заболевания. Их использование в качестве базисной терапии воспаления дыхательных путей снижает частоту обострений БА. В настоящее время изучение фенотипов астмы позволило определить те из них, в которых именно лейкотриены играют ключевую роль. Поэтому применение антагонистов лейкотриеновых рецепторов является важным аспектом противовоспалительной терапии БА.
Study of cysteine leukotrienes, lipoxygenase products of arachidonic acid metabolism as the mediators of inflammation in bronchial asthma (BA) has allowed to develop and implement a relatively new class of drugs – leukotriene receptor antagonists. Their anti-inflammatory action allows to achieve a controlled flow of BA as monotherapy in mild asthma, or in combination with other anti-asthmatic drugs in the more severe cases of the disease. Their use as basic treatment of inflammation of the airways reduces the frequency of exacerbations of asthma. The current study phenotypes of asthma helped identify those in which it leukotrienes play a key role. Therefore, the use of leukotriene receptor antagonists is an important aspect of the anti-inflammatory treatment of asthma.
1. Global Initiative for Asthma. Workshop Report, 2014. http://www.ginasthma.com/ download.asp?intId=217
2. Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/ download.asp?intId=217
3. Gronke L, Kanniess F, Holz O et al. The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clin Exp Allergy 2002; 32: 57–63.
4. O’Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111: 27S–34S
5. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94 (2): 187–226.
6. Holgate S, Dahlen S-E. SRS-A to Leukotrienes, 1997
7. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3: 588–93.
8. Астафьева Н.Г. Астма и спорт. Consilium Medicum. 2008; 10 (1). / Astaf'eva N.G. Astma i sport. Consilium Medicum. 2008; 10 (1). [in Russian]
9. Чучалин А.Г. Спорт и бронхиальная астма. Пульмонол. и аллергол. 2005; 2: 3–5. / Chuchalin A.G. Sport i bronkhial'naia astma. Pul'monol. i allergol. 2005; 2: 3–5. [in Russian]
10. Вылегжанина Т.Г. Взаимосвязь аллергического ринита и бронхиальной астмы. Consilium Medicum. 2001; 3 (12): 579–81. / Vylegzhanina T.G. Vzaimosviaz' allergicheskogo rinita i bronkhial'noi astmy. Consilium Medicum. 2001; 3 (12): 579–81. [in Russian]
11. Philip G, Nayak AS, Berger WE et al. The effct of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20: 1549–58.
12. Shore S. Obesity and asthma: lessons from animal models. J Appl Physiol 2007; 102: 516–28.
13. Price D, Popov TA, Bjermer L et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 2013; 131 (3): 763–71.
14. Chen X, Wang K, Jiang M, Nong GM. Leukotriene receptor antagonists for small-airway abnormalities in asthmatics: a systematic review and meta-analysis. J Asthma 2013; 50 (7): 695–704.
15. Gravett CM, Theron AJ, Steel HC et al. Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. Eur Respir J 2010; 36 (6): 1417–24.
16. Hedman J, Kaprio J, Poussa T et al. Prevalence of asthma, aspirin intolerance, nacal polyposis and chronic obstructive pulmonary disease in population-based study. Int J Epidemiol 1999; 717–22.
17. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Clin Immunol 1999; 104: 5–13.
18. McMains KC; Kountakis, Stilianos E. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol 2006; 20 (6): 573–6.
19. Dahlén SE, Malmström K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (1): 9–14.
20. Park JS, Jang AS, Park SW et al. Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics. Allergy Asthma Immunol Res 2010; 2 (1): 48–54.
21. Schäper C, Noga O, Koch B et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol 2011; 21 (1): 51–8.
22. Bjermer L, Anderson SD. Bronchial hyperrcspoiisiveness in athletes: mechanisms for development. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, icspiialoiy and Allergic Disordes in Sports. Ed. KH.Carlsin, L.Delgado, S.Del Giacco. Eur Resp Monograph 2005; 33: 19–34.
23. Duranti R. Exercise-induced bronchoconstriction: protocols. Study with the experts. Interactive Course on Basic principles of clinical exercise testing. Rome, Italy March 2-4, 2006. ERS School Courses 2006.
24. Hallstrand TS. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr 2002; 141: 343–9.
25. Weiler JM, Layton Т, Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J Allergy Clin Immunol 1998; 102: 722–6.
26. Demoly P, Bousquet J. The relation between asthma and allergic rhinitis. Lancet 2006; 368: 711–13.
27. Thomas M. Allergic rhinitis: evidence for impact on asthma. BMC Pulm Med 2006; 6 (1): 1–7.
28. Paiange R, Brusasco V, Delgado L, Del Giacco S. Exercise and airway pathology: interactions with immune and allergic responses. In: Diagnosis, Prevention and Treatment of Exercise-Related Asthma, respiratory and Allergic Disordes in Sports. Eds. К.Н.Carlsen, L.Delgado, S.Del Giacco. Eur Resp Monograph 2005; 33: 10–8. 17
29. Лопатин А.С., Гущин И.С., Емельянов А.В. и др. Клинические рекомендации по диагностике и лечению аллергического ринита. Consilium Medicum. 2001; 3 (9): 33–44. / Lopatin A.S., Gushchin I.S., Emel'ianov A.V. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniiu allergicheskogo rinita. Consilium Medicum. 2001; 3 (9): 33–44. [in Russian]
30. Price DB, Swern A, Tozzi CA et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT tria. Allergy 2006; 61: 737–42.
31. Keith PK, Koch C, Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16 (Suppl. A): 17A–31A.
32. Beuther DA, Sutherland ER. Overweight, obesity, and incidentasthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007; 175: 661–6.
33. Chalmers GW, Macleod KJ, Little SA et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (3): 226–30.
34. Bjermer L. The role of small airway disease in asthma. Curr Opin Pulm Med 2014; 20 (1): 23–30.
35. Price DB, Swern A, Tozzi CA et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61: 737–42.
36. Keith PK, Koch C, Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16 (Suppl. A): 17A–31A.
37. Vaquerizo MJ, Casan P, Castillo J et al., for the CASIOPEA Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 211–16.
38. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med 2010; 104 (5): 644–51.
39. Bisgaard H, Skoner D, Boza ML et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009; 44 (6): 568–79.
40. Knorr B, Nguyen HH, Kearns GL. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults.
J Clin Pharmacol 2001; 41 (6): 612–9.
41. Hernandez-Alvidrez E, Alba-Reyes G, Munoz-Cedillo BC et al. Passive smoking induces leukotriene production in children: influence of asthma. J Asthma. Epub ahead of print, February 12, 2013.
42. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome. Adverse effect or response to corticosteroid withdrawal? Drug Safety 1999; 21: 241–51.
43. Бондарева И.Б. и др. Проведение качественных исследований биоэквивалентности лекарственных средств. Клин. фармакокинетика. 2005; 1 (2). / Bondareva I.B. i dr. Provedenie kachestvennykh issledovanii bioekvivalentnosti lekarstvennykh sredstv. Klin. farmakokinetika. 2005; 1 (2). [in Russian]
________________________________________________
1. Global Initiative for Asthma. Workshop Report, 2014. http://www.ginasthma.com/ download.asp?intId=217
2. Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/ download.asp?intId=217
3. Gronke L, Kanniess F, Holz O et al. The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clin Exp Allergy 2002; 32: 57–63.
4. O’Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111: 27S–34S
5. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938; 94 (2): 187–226.
6. Holgate S, Dahlen S-E. SRS-A to Leukotrienes, 1997
7. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3: 588–93.
8. Astaf'eva N.G. Astma i sport. Consilium Medicum. 2008; 10 (1). [in Russian]
9. Chuchalin A.G. Sport i bronkhial'naia astma. Pul'monol. i allergol. 2005; 2: 3–5. [in Russian]
10. Vylegzhanina T.G. Vzaimosviaz' allergicheskogo rinita i bronkhial'noi astmy. Consilium Medicum. 2001; 3 (12): 579–81. [in Russian]
11. Philip G, Nayak AS, Berger WE et al. The effct of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20: 1549–58.
12. Shore S. Obesity and asthma: lessons from animal models. J Appl Physiol 2007; 102: 516–28.
13. Price D, Popov TA, Bjermer L et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 2013; 131 (3): 763–71.
14. Chen X, Wang K, Jiang M, Nong GM. Leukotriene receptor antagonists for small-airway abnormalities in asthmatics: a systematic review and meta-analysis. J Asthma 2013; 50 (7): 695–704.
15. Gravett CM, Theron AJ, Steel HC et al. Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. Eur Respir J 2010; 36 (6): 1417–24.
16. Hedman J, Kaprio J, Poussa T et al. Prevalence of asthma, aspirin intolerance, nacal polyposis and chronic obstructive pulmonary disease in population-based study. Int J Epidemiol 1999; 717–22.
17. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Clin Immunol 1999; 104: 5–13.
18. McMains KC; Kountakis, Stilianos E. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol 2006; 20 (6): 573–6.
19. Dahlén SE, Malmström K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165 (1): 9–14.
20. Park JS, Jang AS, Park SW et al. Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics. Allergy Asthma Immunol Res 2010; 2 (1): 48–54.
21. Schäper C, Noga O, Koch B et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol 2011; 21 (1): 51–8.
22. Bjermer L, Anderson SD. Bronchial hyperrcspoiisiveness in athletes: mechanisms for development. Diagnosis, Prevention and Treatment of Exercise-Related Asthma, icspiialoiy and Allergic Disordes in Sports. Ed. KH.Carlsin, L.Delgado, S.Del Giacco. Eur Resp Monograph 2005; 33: 19–34.
23. Duranti R. Exercise-induced bronchoconstriction: protocols. Study with the experts. Interactive Course on Basic principles of clinical exercise testing. Rome, Italy March 2-4, 2006. ERS School Courses 2006.
24. Hallstrand TS. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr 2002; 141: 343–9.
25. Weiler JM, Layton Т, Hunt M. Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J Allergy Clin Immunol 1998; 102: 722–6.
26. Demoly P, Bousquet J. The relation between asthma and allergic rhinitis. Lancet 2006; 368: 711–13.
27. Thomas M. Allergic rhinitis: evidence for impact on asthma. BMC Pulm Med 2006; 6 (1): 1–7.
28. Paiange R, Brusasco V, Delgado L, Del Giacco S. Exercise and airway pathology: interactions with immune and allergic responses. In: Diagnosis, Prevention and Treatment of Exercise-Related Asthma, respiratory and Allergic Disordes in Sports. Eds. К.Н.Carlsen, L.Delgado, S.Del Giacco. Eur Resp Monograph 2005; 33: 10–8. 17
29. Lopatin A.S., Gushchin I.S., Emel'ianov A.V. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniiu allergicheskogo rinita. Consilium Medicum. 2001; 3 (9): 33–44. [in Russian]
30. Price DB, Swern A, Tozzi CA et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT tria. Allergy 2006; 61: 737–42.
31. Keith PK, Koch C, Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16 (Suppl. A): 17A–31A.
32. Beuther DA, Sutherland ER. Overweight, obesity, and incidentasthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007; 175: 661–6.
33. Chalmers GW, Macleod KJ, Little SA et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57 (3): 226–30.
34. Bjermer L. The role of small airway disease in asthma. Curr Opin Pulm Med 2014; 20 (1): 23–30.
35. Price DB, Swern A, Tozzi CA et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61: 737–42.
36. Keith PK, Koch C, Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16 (Suppl. A): 17A–31A.
37. Vaquerizo MJ, Casan P, Castillo J et al., for the CASIOPEA Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 211–16.
38. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med 2010; 104 (5): 644–51.
39. Bisgaard H, Skoner D, Boza ML et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009; 44 (6): 568–79.
40. Knorr B, Nguyen HH, Kearns GL. Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults.
J Clin Pharmacol 2001; 41 (6): 612–9.
41. Hernandez-Alvidrez E, Alba-Reyes G, Munoz-Cedillo BC et al. Passive smoking induces leukotriene production in children: influence of asthma. J Asthma. Epub ahead of print, February 12, 2013.
42. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome. Adverse effect or response to corticosteroid withdrawal? Drug Safety 1999; 21: 241–51.
43. Bondareva I.B. i dr. Provedenie kachestvennykh issledovanii bioekvivalentnosti lekarstvennykh sredstv. Klin. farmakokinetika. 2005; 1 (2). [in Russian]
Авторы
Н.П.Княжеская*
ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*kniajeskaia@mail.ru
________________________________________________
N.P.Kniazheskaia*
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*kniajeskaia@mail.ru